Heteromultivalent Polymers and Antiviral Applications Thereof

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention describes heteromultivalent polymers that have a linear, biocompatible polymer backbone decorated with both hemagglutinin-binding and neuraminidase-binding groups. These dual-action polymers can bind to crucial proteins on viral surfaces (such as influenza viruses), thereby blocking both viral entry into host cells and the release of new virus particles. The invention further covers pharmaceutical compositions containing these polymers, particularly for the prevention and treatment of viral infections like influenza.

Use CasesContent extracted from patent full text and abstract with AI.

• Development of antiviral drugs for influenza, including drug-resistant strains.
• Preventive sprays or aerosols for high-risk populations during flu outbreaks.
• Therapeutic treatments for patients already infected with influenza A or B.
• Hospital or clinic-based infection control to lower transmission rates.
• Potential adaptation for other viruses with similar surface proteins (e.g., parainfluenza, mumps).
• Use in veterinary medicine to prevent or treat viral outbreaks in animals.

BenefitsContent extracted from patent full text and abstract with AI.

• Dual targeting significantly reduces the ability of the virus to infect and propagate, increasing efficacy over single-target drugs.
• Synergistic effect: Covalent incorporation of both functional groups on the same polymer backbone provides stronger antiviral activity than physical mixtures of single-function polymers or homomultivalent nanoparticles.
• Broad-spectrum activity: Effective against multiple influenza strains and serotypes, including those resistant to neuraminidase inhibitors.
• High safety margin: Compounds are non-toxic at concentrations much higher than the therapeutic dose.
• Formulation flexibility: Can be delivered as aerosols for nasal or pulmonary administration, suitable for both preventative and therapeutic uses.
• Potential for scalability and ease of manufacture using biocompatible polymers.
• Reduced potential for drug resistance compared to traditional monotherapy agents.
• Outperforms prior art in efficacy and safety.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to heteromultivalent polymers comprising a linear polymer backbone, wherein said backbone is substituted with at least one hemagglutinin binding moiety and at least one neuraminidase binding moiety, pharmaceutical compositions comprising the same and their medical use, in particular for viral infections.